
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.


Cho, Myung-Hwan The Microbiological Society of Korea 1990 微生物과 産業 Vol.16 No.2
This paper outlines research to study two aspects of Cryptooridium. First, specific antigenic determinants were identified and followed through the growth cycle of C. parvum to investigate antigenic sharing of molecular epitopes among the different life cycle stages. Secondly, the importance of passive immune protective mechanisms in cryptosporidial infection was assessed by following the course of infection in neonatal mice which have been subjected to treatments using either monoclonal antibodies (mAbs) or hyperimmune bovine colostrum.
Myung Hwan Bae,Yongkeun Cho,Jongmin Hwang,Hyoung-Seob Park,Seongwook Han,Young Soo Lee,Hyun Jun Cho,정병천,Chan-Hee Lee,Dae-Woo Hyun,Jong Sung Park,Jinhee Ahn,Ki-Hun Kim,신동구 대한의학회 2020 Journal of Korean medical science Vol.35 No.9
Background: Studies on the efficacy of implantable cardioverter-defibrillator (ICD) therapy for primary prevention in Asian patients are relatively lacking compared to those for secondary prevention. Also, it is important to stratify which patients will benefit from ICD therapy for primary prevention. Methods: Of 483 consecutive patients who received new implantation of ICD in 9 centers in Korea, 305 patients with reduced left ventricular systolic function and/or documented ventricular fibrillation/tachycardia were enrolled and divided into primary (n = 167) and secondary prevention groups (n = 138). Results: During mean follow-up duration of 2.6 ± 1.6 years, appropriate ICD therapy occurred in 78 patients (25.6%), and appropriate ICD shock and anti-tachycardia pacing occurred in 15.1% and 15.1% of patients, respectively. Appropriate ICD shock rate was not different between the two groups (primary 12% vs. secondary 18.8%, P = 0.118). However, appropriate ICD therapy rate including shock and anti-tachycardia pacing was significantly higher (primary 18% vs. secondary 34.8%, P = 0.001) in the secondary prevention group. Type of prevention and etiology, appropriate and inappropriate ICD shock did not affect all-cause death. High levels of N-terminal pro-B-type natriuretic peptide, New York Heart Association functional class, low levels of estimated glomerular filtration ratio, and body mass index were associated with death before appropriate ICD shock in the primary prevention group. When patients were categorized in 5 risk score groups according to the sum of values defined by each cut-off level, significant differences in death rate before appropriate ICD shock were observed among risk 0 (0%), 1 (3.6%), 2 (3%), 3 (26.5%), and 4 (40%) (P < 0.001). Conclusion: In this multicenter regional registry, the frequency of appropriate ICD therapy is not low in the primary prevention group. In addition, combination of poor prognostic factors of heart failure is useful in risk stratification of patients who are not benefiting from ICD therapy for primary prevention.




Immunologic and Virologic Response of Human Immunodeficiency Virus Type I to Zidovudine Monotherapy
Cho,Myung-Hwan 建國大學校基礎科學硏究所 1998 理學論集 Vol.23 No.-
HIV 질병에서 환자의 혈액 속에 있는 HIV의 수의 측정이 가능하게 되면서 질병관리에 새로운 전환점이 마련되었다. 이러한 측정은 환자의 몸 속에서 HIV 돌연변이주의 출현을 알아낼 수 있게 되었다. zidovudine으로 치료를 시작하게 되면서 HIV-1 역전사효소 유전자에 돌연변이가 일어나면서 내성이 생기는 것은 에이즈 치료에 큰 문제로 등장하였다. zidovudine에 대한 HIV-1의 면역학적 및 바이러스학적 반응을 조사하기 위하여 HIV-1 RNA와 CD4 세포 수의 변화를 측정하였다. 8주가 경과되면 서 HIV-1 RNA 수가 현저히 줄어들면서 24 주가 될 때 최저치를 보였다. 반대로 CD4 세포는 24주가 되면서 최대 수치에 도달하였다. 그러나 48주가 되면서 치료 받기 전의 상태로 되돌아 감으로서 HIV-1 돌연변이주의 출현을 확인하였다. The ability to quantitate human immunodeficiency virus (HIV) in blood from patients at all stages of disease has provided new insights into the pathogenesis of HIV disease. With the widespread use of zidovudine (ZDV) in human immunodeficiency virus infection, drug resistant virus resulting from mutations in the HIV reverse transcriptase gene is an increasing problem. The response of HIV-1 to intial ZDV treatment was assessed in which serum HIV-1 concentrations and CD4 cell count were quantified. There was a prompt fall in serum HIV-1 RNA within 8 weeks of treatment with maximum suppression at week 24. CD4 cell count at week 24 was much higher than the value at baseline. However, both serum RNA load and CD4 cell count started to retum to pretreatment levels at week 48, ascertaining the appearance of a drug resistnat strain of HIV-1.

